VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Abeona Therapeutics Executive Compensation (FY25)

ABEO · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Vishwas Seshadri
Latest say-on-pay support
=
June 12, 2026
Free for 3 days · no card

See how Abeona Therapeutics’s pay stands against its peers

  • Abeona Therapeutics's company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ABEOSee the plan and pricing
No card. Nothing is charged, and the trial ends on its own. After the trial: $499/month, or $5,000/year, about two months free.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
158 figures on this page: 152 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Vishwas Seshadri: $3,506,708 → $3,991,516 (13.8% higher)
Say-on-pay support: 94.0% → 78.4% (15.6 points lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Abeona Therapeutics' chief executive and what were they paid?
Vishwas Seshadri was paid $3,991,516 in total compensation as President and Chief Executive Officer for fiscal 2025. Seshadri's total was 13.8% higher than the $3,506,708 reported for fiscal 2024.
What was Abeona Therapeutics' say-on-pay result?
The say-on-pay proposal drew 78.4% of votes cast including abstentions in favor at the meeting held June 12, 2026 for fiscal 2025.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Vishwas Seshadri
President and Chief Executive Officer
◇◇◇—◇—◇◇
Brendan O’Malley
General Counsel
◇◇◇—◇—◇◇
Joseph Vazzano
Chief Financial Officer
◇◇◇—◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Vishwas Seshadri
President and Chief Executive Officer
◇◇◇—◇—◇◇
Joseph Vazzano
Chief Financial Officer
◇◇◇—◇—◇◇
Brendan O’Malley
General Counsel
◇◇◇—◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Vishwas Seshadri
President and Chief Executive Officer
◇◇◇—◇—◇◇
Joseph Vazzano
Chief Financial Officer
◇◇◇—◇—◇◇
Brendan O’Malley
General Counsel
◇◇◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Vishwas Seshadri
President and Chief Executive Officer
◇◇◇—◇—◇◇
Joseph Vazzano
Chief Financial Officer
◇◇◇—◇—◇◇
Brendan O’Malley
Chief Legal Officer
◇◇◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Joseph VazzanoRSA◇——◇———
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Vishwas SeshadriRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Joseph VazzanoRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Leila Alland, M.D
◇◇————◇
Michael Amoroso
Board chair
◇◇————◇
Mark J. Alvino
◇◇————◇
Faith L. Charles
◇◇————◇
Donald A. Wuchterl
◇◇————◇
Bernhardt G. Zeiher, M.D
◇◇————◇
Eric Crombez, M.D
◇◇————◇
Christine Silverstein
◇◇————◇
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Restricted Stock.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 12, 2026=◇◇◇
2024May 19, 2025=◇◇◇
2022May 17, 2023=◇◇◇
2021August 17, 2022=◇◇◇
2018May 28, 2019=◇◇◇
2015May 12, 2016=◇◇◇
Tell me when Abeona Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Abeona Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Abeona Therapeutics' disclosed peer group is defensible, who names Abeona Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
158 figures on this page: 152 cited to the filing that reported them, 6 calculated from figures it prints.
152 cited to the filing
6 calculated from the filing

Documents cited

  1. 0001493152-26-028458
    Item 5.07 Submission of Matters to a Vote of Security Holders.
  2. 0001493152-26-019153
    COMPENSATION OF DIRECTORS
  3. 0001641172-25-011452
    Item 5.07 Submission of Matters to a Vote of Security Holders.
  4. 0001493152-24-044862
  5. 0001493152-23-017946
    Item 5.07 Submission of Matters to a Vote of Security Holders.
  6. 0001493152-23-012135
  7. 0001493152-22-023332
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  8. 0001144204-19-028638
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  9. 0001144204-16-103122
    Item 5.07. Submission of Matters to a Vote of Security Holders.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Abeona Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/ABEO (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Abeona Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

Biopharma & Life Sciences rankings

Terms on this page

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}